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Abstract 
Background: Studies have reported increases in clinically diagnosed and treated Attention 
deficit hyperactivity disorder (ADHD) during the last decade, but it is unclear if this reflects 
an increase in the underlying ADHD phenotype. We aimed to clarify if there has been an 
increase in the prevalence of ADHD-like traits in the general population from 2004 to 2014.  
Method: Data were collected from 19,271 nine-year old twins, participating in the 
population-based Child and Adolescent Twin Study in Sweden between 2004 and 2014. We 
assessed lifetime ADHD symptoms using the Autism-Tics, ADHD and other Comorbidities 
inventory. Research proxies for diagnostic level ADHD and subthreshold ADHD were derived 
from this scale. We modelled the lifetime prevalence of diagnostic level and subthreshold 
ADHD with logistic regression, and assessed mean ADHD scores each year with linear 
regression. Lifetime prevalence of clinically diagnosed ADHD was retrieved from the 
National Patient Register and modelled with logistic regression.  
Results: The prevalence of diagnostic level ADHD based on parent ratings did not differ 
significantly over time from 2004 to 2014 (OR 1.37; 95% CI: 0.77-2.45; p-value .233). Both 
subthreshold ADHD and mean ADHD scores increased significantly over time (both p-values 
< .001). Clinically diagnosed ADHD increased more than five-fold from 2004 to 2014 (OR 
5.27, 95% CI 1.85-14.96). 
Conclusion: We found no evidence of an increase of ADHD-like traits at the extreme end of 
the distribution from 2004-2014, but small increases in normal and subthreshold variations of 
ADHD-like traits were observed. This suggests that the increased rates of clinically diagnosed 
ADHD might reflect changes in diagnostic and treatment practices of ADHD, administrative 
changes in reporting diagnoses, greater awareness of ADHD, better access to healthcare, or 
current over-diagnosis, rather than an increase in the ADHD phenotype. 
Keywords: ADHD; epidemiology; time trends; lifetime prevalence  
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INTRODUCTION 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder, with a 
worldwide prevalence of around 5% (Polanczyk, de Lima, Horta, Biederman & Rohde, 2007). 
ADHD is usually diagnosed in childhood, with a higher prevalence among boys than girls, 
and is more common in lower socio-economic strata (Biederman & Faraone, 2005). 
Furthermore, at least half of the children with ADHD continue to have impairing symptoms 
as adults (Biederman et al., 2005), and it is associated with adverse outcomes such as poor 
school achievement, financial problems, criminality, accidents, substance use disorder and an 
increased risk of psychiatric problems (Klein et al., 2012). 
 
Several studies from different countries suggest that the prevalence of clinically diagnosed 
ADHD has increased substantially over time. In a population-based study from Finland, 
Denmark and Sweden, Atladottir et al. found that the age-specific prevalence of clinically 
diagnosed ADHD increased among 10-year olds in all three countries (1.83-fold in Finland, 
2.95-fold in Denmark and 7.21-fold in Sweden) during the period 1990 to 2007 (Atladottir et 
al., 2015). In a Swedish population-based study, Giacobini et al. showed that the one-year 
prevalence of clinical diagnoses increased more than four-fold, and the annual incidence 
increased more than two-fold, from 2006 to 2011 (Giacobini, Medin, Ahnemark, Russo & 
Carlqvist, DOI: 10.1177/1087054714554617). A similar trend has been shown in a Taiwanese 
study based on insurance records, with a 27-fold increase in the one-year prevalence of 
clinically diagnosed ADHD in children from 1996 to 2005, and a 17-fold increase in the 
incidence from 1997 to 2005 (Chien, Lin, Chou & Chou, 2012). Similar patterns have been 
found in the US as well. In studies based on surveys conducted with US office-based 
physicians, the one-year prevalence of clinical diagnoses among 5-18 years old children 
increased three-fold from 1990 to 1998 (Robison, Skaer, Sclar & Galin, 2002), and the 
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biannual prevalence increased four-fold from 1991 to 2008, when the same data was analyzed 
ten years later (Sclar et al., 2012). Similarly, the lifetime prevalence of diagnosed ADHD 
increased with 42% from 2003 to 2011 in a population-based study of 4-17 year old children, 
where parents were asked to report whether their children had ever received an ADHD 
diagnosis by a physician (Visser et al., 2014).  
 
A similar trend has been documented for the prevalence of dispensed ADHD medication, both 
in Sweden (Zetterqvist, Asherson, Halldner, Långström & Larsson, 2013) and in other 
western countries (Renoux, Shin, Dell'Aniello, Fergusson & Suissa, 2016, Beau-Lejdstrom, 
Douglas, Evans & Smeeth, 2016, Zito et al., 2003, Trip, Visser, Kalverdijk & de Jong-van 
den Berg, 2009). The one-year prevalence of dispensed ADHD medication has increased 7.5-
fold from 1996 to 2006 in the Netherlands (Trip et al., 2009), and 2.28-fold from 2006-2009 
in Sweden (Zetterqvist et al., 2013), based on population-based registers of prescribed 
medication. Data from insurance records in the US similarly showed a two to three-fold 
increase in the one-year prevalence of dispensed ADHD medication among children during 
the period 1987 to 1996 (Zito et al., 2003). Similarly, two studies of patients registered in a 
medical records database in the UK, have shown that the one-year prevalence of prescribed 
ADHD medication increased 34-fold among children from 1995 to 2013 (Beau-Lejdstrom et 
al., 2016), and almost nine-fold among all 6-45 year old patients 2000 to 2015 (Renoux et al., 
2016). 
 
Despite the different study populations and different methods used, these previous studies all 
point towards increasing rates of clinically diagnosed and treated ADHD. However, it has 
been suggested that even though rates of clinically diagnosed ADHD have increased, ADHD 
symptoms seem to have been stable over time (Safer, DOI: 10.1177/1087054715586571), 
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which suggests that the increase seen in studies based on clinical diagnosis does not 
necessarily reflect an increase in the underlying ADHD phenotype. Changes in quality of 
data, and administrative changes in reporting diagnoses, are plausible alternative explanations. 
Greater awareness about ADHD among physicians, as well as among parents and teachers, is 
also a likely explanation for the increase in diagnosed and treated ADHD. A greater 
awareness among physicians could also have resulted in fewer misdiagnosed individuals, and 
more individuals receiving proper treatment. Furthermore, better access to healthcare might 
explain the increase seen in some countries (Chien et al., 2012). This increase might also be 
influenced by changes in the classification systems used as the diagnostic criteria for ADHD 
has evolved over a period of 20-30 years, (Faraone, Sergeant, Gillberg & Biederman, 2003) 
which gradually causes changes in diagnostic practice.  
 
To explore potential changes in the prevalence of ADHD over time, Polanczyk et al. recently 
conducted a large meta-analysis of non-referred samples, based on 135 worldwide studies 
conducted during a period of 30 years (Polanczyk, Willcutt, Salum, Kieling & Rohde, 2014). 
This study found no evidence of an increase in the prevalence of ADHD, speaking against an 
increase in the underlying ADHD phenotype. However, the meta-analysis had some 
limitations as several different measures of ADHD were used in the studies (including e.g. 
both clinical diagnosis as well as parental reports), individuals in different ages were included, 
and publication year was used as a proxy since information about which year the study was 
conducted was not always available (Polanczyk et al., 2014). 
 
There is a need for studies based on cohorts of individuals of the same age, conducted in the 
same location for a longer period of time, using a stable and validated measure of ADHD. In 
this study, we aimed to clarify if the lifetime prevalence of ADHD-like traits in nine year old 
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children has increased in Sweden during the last decade. Based on the meta-analysis by 
Polanczyk et al., where no increase was found in the prevalence of ADHD in population-
based samples worldwide, we hypothesized that the underlying ADHD phenotype has been 
stable over time.  
 
METHODS 
Study population and data collection 
Data were collected from participants in the Child and Adolescent Twin Study in Sweden 
(CATSS). CATSS is an ongoing study of all nine-year old twins in Sweden, and was initiated 
in 2004 with the purpose to study physical and mental health problems in twins during 
childhood and adolescence (Anckarsäter et al., 2011). Parents of all twins in Sweden are 
contacted during the year the twins turn 9 and asked to participate in a telephone interview 
(see below). Parents of 27,820 children (13,910 twin pairs) born from 1st of July 1995 to 31st 
of December 2005 were asked to participate in CATSS during the years 2004-2014. Of these, 
parents of 19,358 twins (corresponding to 9,679 pairs) participated, yielding an overall 
response rate of 69.6%. Non-responders were more likely than responders to have a parent 
treated in psychiatric clinics, a parent convicted of a crime, divorced parents, or to belong in 
low socio-economic strata (Anckarsäter et al., 2011). Non-responders also had higher 
prevalence of disorders such as ADHD (2.1% versus 1.6%), and higher prevalence of 
prescribed ADHD medication (1.8% compared with 1.4%) (Anckarsäter et al., 2011). 
Individuals with missing information on ADHD were excluded from the analysis (n=87), 
yielding a final analytical sample of 19,271 children from 9,673 families. Parents gave their 
informed consent for themselves and their children to participate in the study. The study was 
approved by the Regional Ethical Review Board in Stockholm (DNR: 02-289 and 2010/597-
31/1).  
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Measures 
Data on ADHD traits were assessed using the Autism-Tics, ADHD and other Comorbidities 
inventory (A-TAC) (Hansson et al., 2005), which was administered to parents. A-TAC is an 
instrument that was developed to measure child and adolescent mental health problems in 
large-scale epidemiological studies, based on telephone ratings conducted by lay interviewers. 
The instrument was developed to capture DSM-IV symptom descriptions. The ADHD-scale 
consists of 19 statements, each with the following response options: “no”, “yes, to some 
extent”, and “yes” (coded as 0/0.5/1). These statements are asked in a lifetime perspective, i.e. 
parents are asked to consider if the child either has these problems/difficulties currently, or 
earlier in life. These 19 items were summarized into a total index for all individuals who 
responded to at least 17 items, thereby ranging from 0 to 19. The scale has been shown to 
have good reliability, with intraclass coefficients of 0.89 and 0.84 for intra-rater and inter-
rater respectively, and a Cronbach’s α of 0.92 (Larson et al., 2014, Anckarsäter et al., 2011). 
The ADHD scale also consists of two subscales, measuring the two dimensions of ADHD: 
attention deficit/concentration, which consists of 9 items and ranges from 0-9, and 
hyperactivity/impulsivity, consisting of 10 items and thereby ranging from 0 to 10. A cut-off 
of ≥12.5 on the ADHD-scale has been clinically validated to correspond to a clinical research 
diagnosis of ADHD (diagnostic level ADHD). This cut-off had a sensitivity of 0.56 and 
specificity of 0.93 when clinical cases were compared cross-sectionally to controls, and a 
sensitivity of 0.20 and specificity of 0.97 when assessed in a clinical longitudinal follow-up 
study(Larson et al., 2010, Larson et al., 2013). Moreover, a cut-off of ≥6 has been used to 
identify subthreshold ADHD, used for screening diagnosis in surveys. This cut-off had a 
sensitivity of 0.91 and specificity of 0.73 in cross-sectional comparisons of clinical cases and 
controls, and a sensitivity of 0.64 and specificity of 0.78 when assessed in a clinical 
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longitudinal follow-up study (Larson et al., 2010, Larson et al., 2013). These two categorical 
measures were not mutually exclusive; individuals with a score ≥12.5 were considered to 
fulfill the criteria for diagnostic level ADHD, as well as for subthreshold ADHD.  
 
The items measuring ADHD in A-TAC have been the same over time and were asked by 
laymen without any clinical knowledge. Furthermore, the scale was constructed to not 
disclose which questions measured which disorder, and parents were asked to rate their 
children on specific symptoms, rather than report if their child had a diagnosis. Taken 
together, this reduced the risk of bias caused by diagnostic substitution, changes in diagnostic 
criteria or clinical practice, or from increased awareness of ADHD.  
 
In this study, we used three different measures to study trends in the lifetime prevalence of the 
ADHD phenotype over time. First, our main analyses were based on the categorical measure 
previously validated to capture diagnostic level ADHD. We considered an increase in 
diagnostic level ADHD to be clinically relevant. Second, in order to further assess a potential 
increase in the underlying ADHD phenotype, we also assessed the lifetime prevalence of 
subthreshold ADHD over time. Third, in order to investigate changes at the general symptom 
level over time, we assessed the mean scores on the ADHD-scale, including the two 
subscales, over time.  
 
Clinically diagnosed ADHD based on registers 
Since previous attrition analysis has shown that non-responders were more likely to receive an 
ADHD diagnosis than responders (Anckarsäter et al., 2011), and since participation in 
CATSS has declined over time, we were concerned that attrition might influence the trends of 
prevalence studied. Therefore, we performed a sensitivity analysis based on linkage of 
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national Swedish registers. Due to the linkage with national registers, these numbers differ 
slightly from the number of individuals eligible and participating in CATSS. In total, we 
identified 28,378 twins born in Sweden between 1st of July 1995 and 31st of December 2005. 
Twins who had died or emigrated before turning nine years old were excluded (n=1,220), 
resulting in a sample size of 27,158 nine-year old twins who were living in Sweden when they 
were nine years old (2004-2014). Of these, 19,041 participated in CATSS. Through record 
linkage with the National Patient Register (Ludvigsson et al., 2011) we identified children 
who had received at least one ADHD diagnosis (ICD-9: 314; ICD-10: F90) by a physician 
before age 10.  
 
Data analysis 
SAS version 9.4 for Windows (SAS Institute Inc., Cary, N.C., USA) and Stata Statistical 
Software: Release 13 (StataCorp. 2013. College Station, TX: StataCorp LP) were used for all 
analyses.  
 
We used logistic regression to model the lifetime prevalence rate of diagnostic level ADHD 
each year with corresponding 95% Confidence Intervals (CI). To further describe the potential 
increase in the ADHD phenotype throughout the study period, we used logistic regression to 
calculate an odds ratio (OR), comparing the prevalence the first year of study with the last 
year. In secondary analysis, we modelled the lifetime prevalence of subthreshold ADHD in a 
similar manner. Furthermore, we used linear regression models to assess the effect of year on 
mean ADHD scores (and corresponding 95% CIs). Mean scores on the subscales attention 
deficit/concentration and hyperactivity/impulsivity were similarly analyzed. To assess 
potential differences between boys and girls, we repeated all analyses stratifying for sex. 
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Cluster robust sandwich standard errors (Stefanski & Boos, 2002) were used in all analyses to 
account for non-normality in data and dependence between observations.   
 
Sensitivity analyses 
Since twins provide correlated responses, and symptoms might be more likely to be noted in 
one twin if the other is already diagnosed, we repeated the analyses in a subsample consisting 
of one randomly selected twin per pair (n=9,673).  
 
To investigate the potential influence of attrition on trends in prevalence, we used logistic 
regression to model the lifetime prevalence of clinically diagnosed ADHD each year, 
including an interaction term of year and participation in CATSS. We also used this record 
linkage to model the lifetime prevalence of clinically diagnosed ADHD among participants in 
CATSS, in order to compare changes over time in the underlying phenotype (diagnostic level 
ADHD) with ADHD diagnosed by clinicians. It was not possible to analyze clinically 
diagnosed ADHD separately for boys and girls since too few girls had a diagnosis (n=69). 
 
[Insert Table 1 about here] 
 
RESULTS 
Table 1 presents descriptive statistics for twins participating in CATSS 2004 to 2014, 
separately for those born 1995-1998, 1999-2002 and 2003-2005. Of the 19,271 participants, 
50.6% were boys (n=9,759) and 49.4% were girls (n=9,512). Over the ten year study period, 
2.1% (n=406) of participants fulfilled the criteria for diagnostic level ADHD (i.e., had a score 
of 12.5 or more on the ADHD scale). The corresponding proportion of individuals with 
subthreshold ADHD (ADHD score of 6 or more) was 10.7% (n=2,058). The mean score on 
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the ADHD scale was 2.04 (standard deviation, sd: 3.11), with mean values of 1.03 (sd: 1.74) 
and 1.00 (sd: 1.69) on the two subscales attention deficit/concentration and 
hyperactivity/impulsivity respectively. The distribution of ADHD scores over time 
(categorized as 0; 0.5-3; 3.5-5.5; 6-12; and ≥12.5) is shown in Figure S1 (available online). 
Overall, there was no clear difference over time at the extreme end of the distribution, 
whereas there seemed to be a shift towards slightly increased scores at the normal and 
subthreshold level. 
 
[Insert Table 2 about here] 
 
The lifetime prevalence of diagnostic level and subthreshold ADHD is presented in Figure 1 
and Table 2. There was no significant difference in the prevalence of diagnostic level ADHD 
over time (p-value: .233). The prevalence fluctuated around 2% most years, with the lowest 
value in 2009 (1.42%; 95% CI: 0.82-2.01) and highest in 2014 (3.16%; 95% CI: 2.10-4.22). 
Overall, the prevalence increased by 37% during the study period 2004 to 2014, but this 
difference was not statistically significant (OR 1.37; 95% CI: 0.77-2.45). The lifetime 
prevalence of subthreshold ADHD was considerably higher, with the lowest value in 2005 
(9.23%; 95% CI 7.88-10.59) to 14.76 (95% CI: 12.72-16.79) in 2014, and increased 
significantly over time (p-value < .001).  
 
[Insert Figure 1 about here] 
 
Figure 2 shows the lifetime prevalence of diagnostic level (Figure 2A) and subthreshold 
(Figure 2B) ADHD during the study period separately for boys and girls (see Table S1 for 
exact numbers). The lifetime prevalence of both diagnostic level and of subthreshold ADHD 
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was consistently lower among girls compared to boys. Again, there was no statistically 
significant increase in diagnostic level ADHD over time in either boys or girls (p-values .229 
and .865 respectively), whereas subthreshold ADHD increased significantly over time (p-
value .017 for boys and .007 for girls). 
 
[Insert Figure 2 about here] 
 
There was also a significant increase in the mean ADHD scores among the study participants 
over time (Figure 3). The mean score on the total ADHD scale ranged from 1.79 (95% CI 
1.69-1.88) in 2004 to 2.29 (95% CI 2.19-2.40) in 2014 (p-value < .001; β=0.05). A similar 
pattern was found when analyzing mean scores on the attention deficit/concentration and 
hyperactivity/impulsivity subscales (Table 2). These results were consistent across sex, 
although with boys constantly having higher scores than girls (Table S2, available online). 
 
[Insert Figure 3 about here] 
 
Repeating the analyses in a subsample of one randomly selected twin per pair resulted in 
similar estimates for diagnostic level ADHD as when the entire sample was analyzed, with no 
significant difference in the prevalence over time (p-value: 0.88), although with wider 
confidence intervals (Table S3, available online). Furthermore, there was no longer any 
significant difference in the prevalence of subthreshold ADHD over time (p-value: 0.403). 
There was a significant effect of year on mean ADHD scores (p-value: 0.0002), but it was no 
longer linear as the estimates seemed to fluctuate over time (Table S3).   
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Results from the sensitivity analysis of clinically diagnosed children in the National Patient 
Register showed that while there was a significant effect of baseline participation in CATSS 
(p-value .049), there was no significant interaction between year and participation in CATSS 
(p-value .365). This means that although participants differed significantly from non-
participants with regard to receiving an ADHD diagnosis, this did not differ over time.  
 
The lifetime prevalence of clinically diagnosed ADHD increased significantly over time (p-
value < .001). The prevalence was 0.39 (95% CI 0.01-0.77) in 2004, and increased each year 
up until 2013 (prevalence: 2.28; 95% CI 1.52-3.04), to then level off slightly to 2.01 (95% CI 
1.32-2.70) in 2014 (Table S4, available online). Overall, the lifetime prevalence of clinically 
diagnosed ADHD increased more than five-fold from 2004 to 2014 (OR 5.27, 95% CI 1.85-
14.96). 
 
DISCUSSION 
The findings from this cross-sectional study suggest that the lifetime prevalence of ADHD-
like traits at the extreme end of the distribution (corresponding to our category of ADHD 
diagnostic level) has been stable from 2004 to 2014 among nine year olds in Sweden. These 
results were consistent for boys and girls, with a consistently higher lifetime prevalence of 
ADHD in boys. This is in line with findings from the meta-analysis by Polanczyk et al. (2014) 
indicating that the prevalence of ADHD in non-referred samples was stable over a 30 year 
period. Similarly, a recent study of the prevalence of Autism Spectrum Disorders (ASD), 
based on the same data as the present study, has shown that the lifetime prevalence of the 
autism phenotype has been stable over time, contrary to previous reports of an increase in 
clinically diagnosed ASD (Lundstrom, Reichenberg, Anckarsater, Lichtenstein & Gillberg, 
2015). Therefore, it seems unlikely that the increase found in studies based on clinical 
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diagnosis and/or treatment of ADHD would represent a true increase in the prevalence of the 
underlying ADHD phenotype. These findings rather suggest that the increase seen in clinical 
diagnosis and in prescription of ADHD medication might be caused by other factors, such as 
changes in diagnostic and treatment practices of ADHD, administrative changes in reporting 
diagnoses, greater awareness among physicians, parents and teachers, or better access to 
healthcare. 
 
It is also possible that the increase previously seen in diagnosed ADHD might be caused by 
over-diagnosing, for instance due to changed administrative practices in schools where a 
diagnosis is now almost a prerequisite for financial support (Fernell, Landgren, Lindstrom, 
Johnson & Gillberg, 2013), and thus an incentive for school personnel to highlight referral as 
an option, or by neglect in ruling out other diagnoses, both psychiatric and somatic (such as 
metabolic imbalances or thyroid dysfunction). Furthermore, the impairment of symptoms is a 
prerequisite in the diagnostic criteria for ADHD, and a potential neglect to consider 
impairment would most likely result in considerably higher rates of ADHD.   
 
It is possible that the increase found for subthreshold ADHD and mean scores might reflect an 
increase in the number of symptoms, where parents might rate their children to have more 
symptoms now compared with ten years ago. In general, knowledge about ADHD has 
increased during this time period, resulting in a larger familiarity and recognition of ADHD 
symptoms overall. It is important to note the rather small effect size – the mean scores 
increased with half a point on a scale ranging from 0 to 19, corresponding to an increase of 
half a symptom over a ten year study period. Many of the estimates also had overlapping 
confidence intervals. In addition, the total increase in the lifetime prevalence of diagnostic 
level ADHD during the entire study period (2004-2014) was minimal (1.37-fold increase), 
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compared with the more than five-fold increase seen in clinically diagnosed ADHD during the 
same time period. This can also be compared with previous studies on Swedish data, where 
the one-year prevalence increased more than four-fold from 2006 to 2011 (Giacobini et al., 
DOI: 10.1177/1087054714554617), the prevalence of clinically diagnosed ADHD among 10-
year olds increased more than 7-fold from 1990 to 2007 (Atladottir et al., 2015), and the one-
year prevalence of dispensed ADHD medication increased 2.28-fold from 2006 to 2009 
(Zetterqvist et al., 2013). Therefore, it is unlikely that the small increase in the normal and 
sub-threshold variations of ADHD-like traits seen in this study explain the observed increase 
in clinically diagnosed ADHD.  
 
The main strengths of this study include the large sample size, the relatively high response 
rate, the population-based sample, and the long study period. Furthermore, the instrument 
used to measure ADHD-like traits was based on DSM-IV criteria, has been stable over time, 
and has been shown to have good validity. There are some limitations that should be kept in 
mind when interpreting the results from this study. We were concerned that the decreasing 
participation rate in CATSS might have confounded our analyses as non-participants have 
been shown to have higher rates of ADHD (Anckarsäter et al., 2011), especially when taken 
together with the significant increase found regarding subthreshold ADHD and mean ADHD 
scores. However, findings from our sensitivity analysis, where we studied the potential effect 
of attrition on ADHD diagnosis, did not support this notion. The ADHD scale has been 
validated in several studies and consistently shown to have excellent specificity. The 
moderate sensitivity, however, might explain the relatively low rates of diagnostic level 
ADHD seen in this study. Another limitation of the moderate sensitivity is that we may have 
under-estimated changes over time; assuming that the statistically significant increase in 
ADHD symptoms generates an increase in the prevalence of ADHD cases that falls below our 
16 
 
strict criteria for ADHD. Furthermore, ADHD-traits were assess based on parental reports 
only, and did not take into account teacher reports, information about impairment or evaluate 
cross-context manifestations, although the measures were validated against clinical diagnoses 
where these aspects are taken into account. We did not take pharmacological treatment into 
account and there is a possibility that parents might have rated children undergoing 
medication as having fewer symptoms because of treatment, although few children were 
treated with ADHD medication (170 children had at least one filled prescription for ADHD 
medication during the year they turned nine) and questions were asked in a lifetime 
perspective. While these factors might explain the relatively low prevalence seen in this 
sample, they are unlikely to influence the pattern in prevalence over time. A further 
consideration regards the generalizability of results from a sample of twins to singletons. 
However, twins have been shown to be comparable to singletons with regard to traits of 
ADHD (Moilanen et al., 1999), supporting the generalizability of our results to singletons. If 
twins are more (or less) likely to be referred than singletons, and if this type of referral has 
changed over time, it might influence our results regarding clinically diagnosed ADHD. 
However, it seems unlikely that twins should require fewer ADHD-traits, than singletons, in 
order to be assigned a clinical diagnosis. Nevertheless, our study results need to be replicated 
in other settings using other study designs.  
 
CONCLUSION 
In this study, we found no evidence of an increase in the lifetime prevalence of ADHD-like 
traits at the extreme end of the distribution among nine-year olds during the period 2004-
2014, while we cannot rule out a small increase in the normal and sub-threshold variations of 
ADHD-like traits. The increased rates of clinically diagnosed ADHD reported in previous 
studies might therefore be influenced by practical and political factors, such as changes in 
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diagnostic and treatment practices of ADHD, administrative changes in reporting diagnoses, 
greater awareness among physicians, parents and teachers, better access to healthcare, or 
current over-diagnosis of ADHD. 
 
Key points 
 Studies have reported increases in clinically diagnosed and treated ADHD, but it is 
unclear if this reflects an increase in the underlying ADHD phenotype.  
 In this study of almost 20,000 nine-year old twins, the prevalence of diagnostic level 
ADHD did not differ significantly over time. 
 Increased rates of clinically diagnosed ADHD cases in previous studies probably 
reflect changes in diagnostic and treatment practices of ADHD, administrative 
changes in reporting diagnoses, greater awareness of ADHD, better access to 
healthcare, or current over-diagnosis of ADHD, rather than an increase in the ADHD 
phenotype. 
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TABLES AND FIGURES 
Table 1. Descriptive information about study participants. 
 Birth year, categorized* 
 
1995-1998 
(n=6,876) 
1999-2002 
(n=7,628) 
2003-2005 
(n=4,767) 
Diagnostic level ADHD, n (%) 136 (2.0) 149 (2.0) 121 (2.5) 
Subtreshold ADHD, n (%) 690 (10.0) 768 (10.1) 600 (12.6) 
Sex       
Boys, n (%) 3521 (51.2) 3832 (50.2) 2406 (50.5) 
Girls, n (%) 3355 (48.8) 3796 (49.8) 2361 (49.5) 
Zygosity       
Monozygotic, n (%) 1871 (27.2) 1967 (25.8) 1362 (28.6) 
Dizygotic, same sex, n (%) 2474 (36.0) 2672 (35.0) 1589 (33.3) 
Dizygotic, opposite sex, n (%) 2387 (34.7) 2835 (37.2) 1661 (34.8) 
Unknown, n (%) 144 (2.1) 154 (2.0) 155 (3.3) 
Maternal age at child's birth       
25 years or younger, n (%) 874 (12.9) 708 (9.3) 385 (8.1) 
26-30 years, n (%) 2440 (35.9) 2607 (34.2) 1462 (30.7) 
31-35 years, n (%) 2494 (36.7) 2991 (39.2) 1836 (38.6) 
36 years or older, n (%) 992 (14.6) 1317 (17.3) 1075 (22.6) 
Mother's highest achieved education       
Primary and secondary education, n 
(%) 48 (5.3) 270 (3.7) 127 (2.8) 
Upper secondary education, n (%) 341 (37.8) 2768 (37.9) 1362 (29.8) 
Post-secondary education, n (%) 72 (8.0) 654 (8.9) 482 (10.6) 
University education, n (%) 440 (48.8) 3621 (49.5) 2593 (56.8) 
Father's highest achieved education       
Primary and secondary education, n 
(%) 70 (8.7) 495 (7.5) 242 (5.8) 
Upper secondary education, n (%) 404 (50.2) 3231 (48.6) 1887 (45.1) 
Post-secondary education, n (%) 36 (4.5) 412 (6.2) 369 (8.8) 
University education, n (%) 294 (36.6) 2504 (37.7) 1690 (40.4) 
Mother's country of birth       
Sweden, n (%) 6155 (89.8) 6889 (90.5) 4236 (89.0) 
Other country, n (%) 699 (10.2) 720 (9.5) 524 (11.0) 
Father's country of birth       
Sweden, n (%) 6077 (88.7) 6783 (89.3) 4224 (88.7) 
Other country, n (%) 773 (11.3) 812 (10.7) 536 (11.3) 
Note: ADHD = attention deficit hyperactivity disorder  
* Data was collected on a yearly bases, but collapsed into categories for this table 
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Table 2. Lifetime prevalence of ADHD, subthreshold ADHD, clinically diagnosed ADHD, and mean ADHD scores among nine-year olds in 
Sweden 2004-2014. 
  Prevalence (95% CI) 
 
Mean scores (95% CI) 
Year 
Diagnostic level 
ADHD  
Subthreshold 
ADHD 
 
ADHD 
Attention deficit/ 
concentration 
Hyperactivity/ 
impulsivity 
2004 2.32 (1.27-3.37) 10.83 (8.83-12.84)  1.79 (1.69-1.88) 0.89 (0.84-0.94) 0.90 (0.84-0.95) 
2005 1.60 (0.98-2.22) 9.23 (7.88-10.59)  1.84 (1.76-1.92) 0.92 (0.88-0.97) 0.92 (0.87-0.96) 
2006 2.00 (1.36-2.65) 9.62 (8.21-11.03)  1.89 (1.82-1.96) 0.95 (0.91-0.99) 0.94 (0.90-0.98) 
2007 
2.16 (1.42-2.89) 10.88 (9.34-12.43) 
 
1.94 (1.88-2.00) 0.98 (0.95-1.01) 0.96 (0.93-0.99) 
2008 2.16 (1.50-2.82) 10.74 (9.22-12.25)  1.99 (1.94-2.04) 1.01 (0.98-1.04) 0.98 (0.95-1.01) 
2009 1.42 (0.82-2.01) 9.37 (7.92-10.83)  2.04 (1.99-2.09) 1.04 (1.01-1.07) 1.00 (0.97-1.03) 
2010 1.82 (1.15-2.48) 9.45 (8.00-10.90)  2.09 (2.04-2.15) 1.07 (1.04-1.10) 1.02 (0.99-1.05) 
2011 2.39 (1.65-3.12) 10.64 (9.12-12.15)  2.14 (2.08-2.20) 1.10 (1.07-1.14) 1.04 (1.01-1.08) 
2012 2.28 (1.57-2.99) 10.93 (9.42-12.45)  2.19 (2.12-2.27) 1.13 (1.09-1.17) 1.06 (1.02-1.10) 
2013 2.31 (1.52-3.10) 12.81 (10.91-14.71)  2.24 (2.15-2.33) 1.16(1.11-1.21) 1.09 (1.04-1.13) 
2014 3.16 (2.10-4.22) 14.76 (12.72-16.79)  2.29 (2.19-2.40) 1.19 (1.13-1.25) 1.11 (1.05-1.16) 
Note: ADHD = attention deficit hyperactivity disorder; CI = Confidence Interval   
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Figure 1. Lifetime prevalence of diagnostic level and subthreshold ADHD among nine-year 
olds in Sweden 2004-2014.  
Note: ADHD = attention deficit hyperactivity disorder 
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Figure 2. Lifetime prevalence of (A) diagnostic level and (B) subthreshold ADHD among 
nine-year olds in Sweden 2004-2014, shown separately for boys and girls.  
Note: ADHD = attention deficit hyperactivity disorder 
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Figure 3. Mean ADHD score among nine-year olds in Sweden 2004-2014. Total ADHD score 
as well as divided by subtype (attention deficit/concentration and hyperactivity/impulsivity), 
shown for (A) all participants as well as separately for (B) boys and (C) girls.  
Note: ADHD = attention deficit hyperactivity disorder 
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SUPPLEMENTARY MATERIAL 
Supplementary Figure 1. Distribution of ADHD scores among participants across the study 
period 2004-2014, shown for (A) all participants, and separately for (B) boys and (C) girls. 
 
 
 
 
 
  
 
 
Supplementary Table 1. Lifetime prevalence of diagnostic level and subthreshold ADHD 
among nine-year olds in Sweden 2004-2014, shown separately for boys and girls 
    
Diagnostic level ADHD (95% CI) Subthreshold ADHD (95% CI) 
Year 
No of 
participants Boys Girls Boys Girls 
2004 1,034 2.97 (1.45-4.49) 1.62 (0.26-2.97) 13.17 (10.14-16.21) 8.28 (5.75-10.82) 
2005 1,939 2.01 (1.02-3.00) 1.17 (0.42-1.91) 12.36 (10.25-14.48) 5.93 (4.28-7.58) 
2006 2,047 2.42 (1.47-3.37) 1.54 (0.67-2.41) 12.21 (10.09-14.33) 6.78 (5.08-8.47) 
2007 1,856 3.17 (1.93-4.41) 1.17 (0.37-1.97) 13.68 (11.29-16.07) 8.17 (6.27-10.08) 
2008 1,993 2.81 (1.72-3.90) 1.50 (0.75-2.26) 13.65 (11.31-16.00) 7.82 (6.09-9.56) 
2009 1,835 1.86 (0.84-2.87) 0.98 (0.34-1.61) 11.79 (9.58-14.00) 6.96 (5.15-8.78) 
2010 1,873 2.73 (1.62-3.83) 0.87 (0.14-1.60) 12.68 (10.43-14.94) 6.09 (4.39-7.80) 
2011 1,927 3.83 (2.60-5.06) 0.94 (0.26-1.61) 14.39 (11.99-16.76) 6.87 (5.16-8.58) 
2012 1,976 3.09 (1.92-4.27) 1.44 (0.64-2.23) 12.57 (10.33-14.82) 9.24 (7.32-11.16) 
2013 1,429 3.40 (2.08-4.72) 1.24 (0.44-2.05) 16.01 (13.08-18.93) 9.68 (7.34-12.03) 
2014 1,362 4.30 (2.61-5.98) 1.96 (0.75-3.16) 18.34 (15.30-21.38) 10.99 (8.52-13.47) 
Note: ADHD = attention deficit hyperactivity disorder; CI = Confidence Interval 
 
 
 
  
 
 
Supplementary Table 2. Mean ADHD score among nine-year olds in Sweden 2004-2014. Total score as well as divided by subtype (attention 
deficit/concentration and hyperactivity/impulsivity), shown separately for boys and girls 
 
Mean scores (95% CI) 
 
ADHD  Attention deficit/concentration Hyperactivity/impulsivity 
Year Boys Girls Boys Girls Boys Girls 
2004 2.19 (2.05-2.33) 1.36 (1.24-1.48) 1.12 (1.04-1.20) 0.65 (0.59-0.72) 1.07 (0.99-1.15) 0.71 (0.65-0.77) 
2005 2.24 (2.12-2.37) 1.41 (1.31-1.51) 1.15  (1.08-1.22) 0.68 (0.63-0.74) 1.10 (1.03-1.16) 0.73 (0.68-0.78) 
2006 2.30 (2.19-2.40) 1.46 (1.38-1.55) 1.18 (1.12-1.24) 0.71 (0.67-0.76) 1.12 (1.06-1.17) 0.75 (0.70-0.80) 
2007 2.35 (2.26-2.44) 1.51 (1.44-1.59) 1.21 (1.16-1.26) 0.74 (0.71-0.78) 1.14 (1.09-1.19) 0.77 (0.73-0.81) 
2008 2.40 (2.32-2.48) 1.56 (1.50-1.63) 1.24 (1.20-1.28) 0.78 (0.74-0.81) 1.16 (1.12-1.21) 0.79 (0.76-0.83) 
2009 2.45 (2.38-2.53) 1.62 (1.55-1.68) 1.27 (1.23-1.31) 0.81 (0.77-0.84) 1.19 (1.14-1.23) 0.81 (0.78-0.84) 
2010 2.51 (2.42-2.59) 1.67 (1.60-1.73) 1.30 (1.26-1.35) 0.84 (0.80-0.87) 1.21 (1.16-1.25) 0.83 (0.80-0.87) 
2011 2.56 (2.46-2.65) 1.72 (1.64-1.79) 1.33 (1.28-1.38) 0.87 (0.82-0.91) 1.23 (1.18-1.28) 0.85 (0.81-0.89) 
2012 2.61 (2.50-2.73) 1.77 (1.68-1.86) 1.36 (1.30-1.42) 0.90 (0.85-0.95) 1.25 (1.19-1.31) 0.87 (0.82-0.92) 
2013 2.67 (2.53-2.80) 1.82 (1.71-1.92) 1.39 (1.32-1.47) 0.93 (0.87-0.99) 1.28 (1.20-1.35) 0.89 (0.83-0.95) 
2014 2.72 (2.56-2.87) 1.87 (1.74-1.99) 1.42 (1.34-1.51) 0.96 (0.89-1.03) 1.30 (1.21-1.38) 0.91 (0.84-0.98) 
Note: ADHD = attention deficit hyperactivity disorder; CI = Confidence Interval   
 
 
Supplementary Table 3. Lifetime prevalence of diagnostic level and subthreshold ADHD, and 
mean ADHD score, among nine-year olds in Sweden 2004-2014. Results based on one 
randomly selected twin per pair. 
 
 Diagnostic level ADHD Subthreshold ADHD ADHD score 
Year Prevalence  (95% CI) Prevalence  (95% CI) Mean  (95% CI) 
2004 2.68 (1.30-4.07) 11.30 (8.59-14.02) 2.24 (1.98-2.50) 
2005 1.75 (0.92-2.57) 9.55 (7.70-11.39) 1.87 (1.68-2.07) 
2006 1.66 (0.88-2.44) 10.05 (8.21-11.89) 1.84 (1.65-2.03) 
2007 1.93 (1.05-2.82) 12.14 (10.04-14.24) 2.07 (1.87-2.26) 
2008 2.10 (1.21-2.99) 10.79 (8.87-12.71) 2.06 (1.87-2.25) 
2009 1.41 (0.65-2.17) 8.45 (6.66-10.25) 1.66 (1.47-1.86) 
2010 2.02 (1.12-2.92) 10.21 (8.28-12.15) 1.92 (1.72-2.11) 
2011 2.28 (1.34-3.21) 10.75 (8.80-12.71) 2.14 (1.94-2.33) 
2012 1.92 (1.06-2.77) 11.40 (9.42-13.38) 2.12 (1.93-2.31) 
2013 2.37 (1.26-3.48) 11.58 (9.23-13.92) 2.30 (2.07-2.52) 
2014 2.35 (1.21-3.48) 11.29 (8.92-13.67) 2.24 (2.01-2.47) 
Note: ADHD = attention deficit hyperactivity disorder; CI = Confidence Interval 
 
Supplementary Table 4. Lifetime prevalence of clinically diagnosed ADHD among nine-year 
old twins participating in the Child and Adolescent Twin Study in Sweden 2004-2014 
 Clinically diagnosed ADHD 
Year 
No of diagnosed 
children Prevalence (95% CI) 
2004 4 0.39 (0.01-0.77) 
2005 13 0.69 (0.31-1.06) 
2006 19 0.98 (0.54-1.42) 
2007 14 0.79 (0.38-1.21) 
2008 19 1.00 (0.55-1.45) 
2009 21 1.19 (0.68-1.69) 
2010 31 1.75 (1.14-2.36) 
2011 35 1.82 (1.22-2.42) 
2012 39 1.97 (1.36-2.59) 
2013 34 2.28 (1.52-3.04) 
Note: ADHD = attention deficit hyperactivity disorder; CI = Confidence Interval 
